Comparative Pharmacology
Head-to-head clinical analysis: ANCEF versus ROCEPHIN KIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANCEF versus ROCEPHIN KIT.
ANCEF vs ROCEPHIN KIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
First-generation cephalosporin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
Ceftriaxone is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking, leading to cell lysis and death.
1-2 g IV/IM every 8 hours; maximum 6 g/day.
Adult: 1-2 g IV or IM every 24 hours. Maximum 4 g/day for severe infections.
None Documented
None Documented
1.5-2 hours in adults with normal renal function; prolongs significantly in renal impairment (up to 30 hours in anuria).
Terminal half-life 6-9 hours in healthy adults; prolonged to 12-15 hours in elderly and up to 30 hours in severe renal impairment (CrCl <10 mL/min).
Primarily renal (80-90% unchanged by glomerular filtration and tubular secretion); small amounts biliary (<1%) and fecal.
Renal (33-67% unchanged), biliary (40-50% as active drug and metabolites), fecal (minor).
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic